Side effects loom over Alzheimer’s drugs
The DOI matches its Crossref record.
Abstract
Despite landmark antibody approval, research into brain swelling and bleeding lags
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All three have shown efficacy in clearing Aβ plaque and slowing cognitive decline, but the risks of amyloid-related imaging abnormalities (ARIA) and their treatment costs are noteworthy.422–424”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [424]
Citations
Cites
Still being checked.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Discovery of novel butyrylcholinesterase inhibitors for treating Alzheimer's disease
Sang, Z., Huang, S., Tan, W., Ban, Y., Wang, K., Fan, Y., Chen, H., Zhang, Q., Liang, C., Mi, J., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.030 · Cited by 33
Amro, Z., Collins‐Praino, L. E., & Yool, A. J. (2024) · Bioscience Reports · doi:10.1042/bsr20231725 · Cited by 20
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 19
Xie, Z., Situ, Y., Deng, L., Liang, M., Ding, H., Guo, Z., Xu, Q., Zhu, L., & Shao, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-88134-w · Cited by 19
Metadata
- Authors
- Couzin-Frankel, J.
- Corresponding author
- Couzin-Frankel, Jennifer
- Venue
- Science
- Published
- 2023-08-04
- Volume
- 381
- Issue
- 6657
- Pages
- 466-467
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4385516142
- Cited by
- 31
- References
- 0
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 8 · 2023: 4
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- Alzheimer's disease, adverse drug reactions, anti-amyloid antibodies, cerebral edema, intracranial hemorrhage, amyloid-beta
- MeSH terms
- Alzheimer Disease, Brain, Brain Edema, Humans, Thrombosis, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.